These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 38719318)

  • 1. Comprehensive observational study evaluating the enduring effectiveness of 4CMenB, the meningococcal B vaccine against gonococcal infections in the Northern Territory and South Australia, Australia: study protocol.
    Marshall H; Ward J; Wang B; Andraweera P; McMillan M; Flood L; Bell C; Sisnowski J; Krause V; Webby R; Childs E; Gunathilake M; Egoroff N; Leong L; Lawrence A; Baird R; Freeman K; Menouhos D; Whiley DM; Karnon J; van Hal S; Lahra MM
    BMJ Open; 2024 May; 14(5):e079144. PubMed ID: 38719318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicentre double-blind randomised placebo-controlled trial evaluating the efficacy of the meningococcal B vaccine, 4CMenB (Bexsero), against
    Seib KL; Donovan B; Thng C; Lewis DA; McNulty A; Fairley CK; Yeung B; Jin F; Fraser D; Bavinton BR; Law M; Chen MY; Chow EPF; Whiley DM; Mackie B; Jennings MP; Jennison AV; Lahra MM; Grulich AE
    BMJ Open; 2024 Apr; 14(4):e081675. PubMed ID: 38626958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An open-label randomised controlled trial evaluating the efficacy of a meningococcal serogroup B (4CMenB) vaccine on Neisseria gonorrhoeae infection in gay and bisexual men: the MenGO study protocol.
    Thng C; Semchenko EA; Hughes I; O'Sullivan M; Seib KL
    BMC Public Health; 2023 Mar; 23(1):607. PubMed ID: 36997957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. B Part of It protocol: a cluster randomised controlled trial to assess the impact of 4CMenB vaccine on pharyngeal carriage of
    Marshall HS; McMillan M; Koehler A; Lawrence A; MacLennan JM; Maiden MCJ; Ramsay M; Ladhani SN; Trotter C; Borrow R; Finn A; Sullivan T; Richmond P; Kahler CM; Whelan J; Vadivelu K
    BMJ Open; 2018 Jul; 8(7):e020988. PubMed ID: 29991629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 'Be on the TEAM' Study (Teenagers Against Meningitis): protocol for a controlled clinical trial evaluating the impact of 4CMenB or MenB-fHbp vaccination on the pharyngeal carriage of meningococci in adolescents.
    Carr J; Plested E; Aley P; Camara S; Davis K; MacLennan JM; Gray S; Faust SN; Borrow R; Christensen H; Trotter C; Maiden MCJ; Finn A; Snape MD;
    BMJ Open; 2020 Oct; 10(10):e037358. PubMed ID: 33093030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Observational Study to Assess the Effectiveness of 4CMenB against Meningococcal Disease and Carriage and Gonorrhea in Adolescents in the Northern Territory, Australia-Study Protocol.
    Marshall HS; Andraweera PH; Ward J; Kaldor J; Andrews R; Macartney K; Richmond P; Krause V; Koehler A; Whiley D; Giles L; Webby R; D'Antoine H; Karnon J; Baird R; Lawrence A; Petousis-Harris H; De Wals P; Greenwood-Smith B; Binks M; Whop L
    Vaccines (Basel); 2022 Feb; 10(2):. PubMed ID: 35214767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic Similarity of Gonococcal Homologs to Meningococcal Outer Membrane Proteins of Serogroup B Vaccine.
    Marjuki H; Topaz N; Joseph SJ; Gernert KM; Kersh EN; ; Wang X
    mBio; 2019 Sep; 10(5):. PubMed ID: 31506309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and impact of the 4CMenB vaccine against invasive serogroup B meningococcal disease and gonorrhoea in an infant, child, and adolescent programme: an observational cohort and case-control study.
    Wang B; Giles L; Andraweera P; McMillan M; Almond S; Beazley R; Mitchell J; Lally N; Ahoure M; Denehy E; Koehler A; Flood L; Marshall H
    Lancet Infect Dis; 2022 Jul; 22(7):1011-1020. PubMed ID: 35427492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. B Part of It School Leaver protocol: an observational repeat cross-sectional study to assess the impact of a meningococcal serogroup B (4CMenB) vaccine programme on carriage of
    Marshall HS; McMillan M; Koehler A; Lawrence A; MacLennan J; Maiden M; Ramsay M; Ladhani SN; Trotter C; Borrow R; Finn A; Sullivan T; Richmond P; Kahler C; Whelan J; Vadivelu K
    BMJ Open; 2019 May; 9(5):e027233. PubMed ID: 31064808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating the effectiveness of the 4CMenB vaccine against invasive meningococcal disease and gonorrhoea in an infant, child and adolescent program: protocol.
    Marshall HS; Andraweera PH; Wang B; McMillan M; Koehler AP; Lally N; Almond S; Denehy E; A'Houre M; Giles LC; Flood L
    Hum Vaccin Immunother; 2021 May; 17(5):1450-1454. PubMed ID: 33428528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 4CMenB sustained vaccine effectiveness against invasive meningococcal B disease and gonorrhoea at three years post programme implementation.
    Wang B; Giles L; Andraweera P; McMillan M; Almond S; Beazley R; Mitchell J; Ahoure M; Denehy E; Flood L; Marshall H
    J Infect; 2023 Aug; 87(2):95-102. PubMed ID: 37268223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. VA-MENGOC-BC Vaccination Induces Serum and Mucosal Anti Neisseria gonorrhoeae Immune Responses and Reduces the Incidence of Gonorrhea.
    Reyes Díaz LM; Lastre González MSJB; Cuello M; Sierra-González VG; Ramos Pupo R; Lantero MI; Harandi AM; Black S; Pérez O
    Pediatr Infect Dis J; 2021 Apr; 40(4):375-381. PubMed ID: 33591079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The serogroup B meningococcal outer membrane vesicle-based vaccine 4CMenB induces cross-species protection against Neisseria gonorrhoeae.
    Leduc I; Connolly KL; Begum A; Underwood K; Darnell S; Shafer WM; Balthazar JT; Macintyre AN; Sempowski GD; Duncan JA; Little MB; Rahman N; Garges EC; Jerse AE
    PLoS Pathog; 2020 Dec; 16(12):e1008602. PubMed ID: 33290434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of Neisseria gonorrhoeae With Meningococcal B Vaccine: A Matched Cohort Study in Southern California.
    Bruxvoort KJ; Lewnard JA; Chen LH; Tseng HF; Chang J; Veltman J; Marrazzo J; Qian L
    Clin Infect Dis; 2023 Feb; 76(3):e1341-e1349. PubMed ID: 35642527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of a serogroup B outer membrane vesicle meningococcal vaccine against gonorrhoea: a retrospective observational study.
    Abara WE; Bernstein KT; Lewis FMT; Schillinger JA; Feemster K; Pathela P; Hariri S; Islam A; Eberhart M; Cheng I; Ternier A; Slutsker JS; Mbaeyi S; Madera R; Kirkcaldy RD
    Lancet Infect Dis; 2022 Jul; 22(7):1021-1029. PubMed ID: 35427490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential Coverage of the 4CMenB Vaccine against Invasive Serogroup B
    Mulhall RM; Bennett D; Cunney R; Borrow R; Lucidarme J; Findlow J; Jolley KA; Bray J; Maiden MCJ; Moschioni M; Serino L; Stella M; Medini D
    mSphere; 2018 Aug; 3(4):. PubMed ID: 30135218
    [No Abstract]   [Full Text] [Related]  

  • 17. First statewide meningococcal B vaccine program in infants, children and adolescents: evidence for implementation in South Australia.
    Marshall HS; Lally N; Flood L; Phillips P
    Med J Aust; 2020 Feb; 212(2):89-93. PubMed ID: 31909501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Australian Gonococcal Surveillance Programme Annual Report, 2018.
    Lahra MM; Enriquez RP; George CRR
    Commun Dis Intell (2018); 2020 Feb; 44():. PubMed ID: 32114974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insight into Prevention of Neisseria Gonorrhoeae: A Short Review.
    La Fauci V; Lo Giudice D; Squeri R; Genovese C
    Vaccines (Basel); 2022 Nov; 10(11):. PubMed ID: 36423044
    [No Abstract]   [Full Text] [Related]  

  • 20. Potential impact of vaccination against Neisseria meningitidis on Neisseria gonorrhoeae in the United States: results from a decision-analysis model.
    Régnier SA; Huels J
    Hum Vaccin Immunother; 2014; 10(12):3737-45. PubMed ID: 25483706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.